[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), reported purchasing a total of 6,000 shares of the company's common stock on 08/21/2025 at a weighted-average price of $2.49 per share (individual trade prices ranged from $2.49 to $2.50). After the reported purchase, Mr. Hochman beneficially owns 651,460 shares directly and additional shares indirectly via multiple family trusts (total indirect positions listed: 449,331; 2,000; 2,000; 2,000; 3,140). The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing discloses insider buying by the CEO/chair but does not provide reasons for the transactions.
David P. Hochman, Amministratore Delegato e Presidente di Orchestra BioMed Holdings, Inc. (OBIO), ha riferito di aver acquistato complessivamente 6.000 azioni ordinarie della societ脿 il 21/08/2025 a un prezzo medio ponderato di $2,49 per azione (i singoli ordini andavano da $2,49 a $2,50). Dopo l'acquisto dichiarato, il sig. Hochman detiene direttamente in propriet脿 beneficiaria 651.460 azioni e ulteriori azioni indirettamente tramite pi霉 trust familiari (posizioni indirette totali indicate: 449.331; 2.000; 2.000; 2.000; 3.140). Il Modulo 4 猫 stato firmato da un procuratore il 25/08/2025. La comunicazione evidenzia un acquisto da parte dell'amministratore delegato/presidente ma non fornisce motivazioni per le operazioni.
David P. Hochman, Director Ejecutivo y Presidente de Orchestra BioMed Holdings, Inc. (OBIO), inform贸 la compra de un total de 6.000 acciones ordinarias de la compa帽铆a el 21/08/2025 a un precio promedio ponderado de $2,49 por acci贸n (los precios individuales oscilaron entre $2,49 y $2,50). Tras la compra reportada, el Sr. Hochman posee beneficiariamente 651.460 acciones en forma directa y acciones adicionales de forma indirecta a trav茅s de varios fideicomisos familiares (posiciones indirectas totales indicadas: 449.331; 2.000; 2.000; 2.000; 3.140). El Formulario 4 fue firmado por un apoderado el 25/08/2025. La presentaci贸n revela la compra por parte del CEO/presidente pero no ofrece razones para las transacciones.
David P. Hochman, Orchestra BioMed Holdings, Inc. (OBIO)鞚� 斓滉碃瓴届榿鞛� 瓴� 鞚挫偓須� 鞚橃灔, 鞚� 2025-08-21鞐� 須岇偓 氤错喌欤� 齑� 6,000欤茧ゼ 欤茧嫻 臧�欷戫弶攴� $2.49鞐� 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟(臧滊硠 瓯半灅臧�電� $2.49~$2.50). 氤搓碃霅� 毵れ垬 頉� Hochman 鞌姅 歆侅爲鞝侅溂搿� 鞙犾澋靻岇湢甓岇溂搿� 651,460欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅� 鞐煬 臧�臁� 鞁犿儊鞚� 韱淀暣 於旉皜搿� 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟(氤搓碃霅� 臧勳爲 氤挫湢 頃╆硠: 449,331; 2,000; 2,000; 2,000; 3,140). Form 4電� 2025-08-25鞐� 雽�毽澑鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�. 鞝滌稖靹滌棎電� CEO/鞚橃灔鞚� 欤检嫕 毵れ垬 靷嫟鞚� 瓿店皽霅橃柎 鞛堨溂雮� 瓯半灅 靷湢電� 旮办灛霅橃柎 鞛堨 鞎婌姷雼堧嫟.
David P. Hochman, Directeur G茅n茅ral et Pr茅sident d'Orchestra BioMed Holdings, Inc. (OBIO), a d茅clar茅 avoir achet茅 au total 6 000 actions ordinaires de la soci茅t茅 le 21/08/2025 脿 un prix moyen pond茅r茅 de 2,49 $ par action (les prix des transactions individuelles variaient de 2,49 $ 脿 2,50 $). Apr猫s cet achat d茅clar茅, M. Hochman d茅tient directement 脿 titre b茅n茅ficiaire 651 460 actions et des actions suppl茅mentaires indirectement via plusieurs trusts familiaux (positions indirectes totales indiqu茅es : 449 331; 2 000; 2 000; 2 000; 3 140). Le formulaire 4 a 茅t茅 sign茅 par un mandat茅 le 25/08/2025. Le d茅p么t r茅v猫le un achat d'initi茅 par le PDG/pr茅sident mais ne fournit pas les raisons des op茅rations.
David P. Hochman, Chief Executive Officer und Vorsitzender von Orchestra BioMed Holdings, Inc. (OBIO), meldete den Kauf von insgesamt 6.000 Stammaktien des Unternehmens am 21.08.2025 zu einem gewichteten Durchschnittspreis von $2,49 je Aktie (Einzelhandelspreise lagen zwischen $2,49 und $2,50). Nach dem gemeldeten Erwerb besitzt Herr Hochman unmittelbar vorteilsberechtigt 651.460 Aktien sowie weitere Aktien indirekt 眉ber mehrere Familienstiftungen (angegebene indirekte Positionen gesamt: 449.331; 2.000; 2.000; 2.000; 3.140). Das Formular 4 wurde am 25.08.2025 von einem Bevollm盲chtigten unterzeichnet. Die Meldung zeigt einen Insiderkauf durch den CEO/Vorsitzenden, nennt jedoch keine Gr眉nde f眉r die Transaktionen.
- Insider purchase reported: CEO/chair acquired 6,000 shares on 08/21/2025 at a weighted-average price of $2.49.
- Substantial insider ownership remains: Reporting person holds 651,460 shares directly and meaningful indirect trust holdings, indicating alignment with shareholders.
- None.
Insights
TL;DR: CEO and chair purchased a small number of shares, modestly increasing his direct stake, which signals insider confidence but is not a material shift.
The acquisition of 6,000 shares by the CEO/chair at about $2.49 per share is a standard insider purchase disclosed on Form 4. The filing shows substantial existing ownership (over 651k shares directly plus meaningful indirect trust holdings), indicating long-standing insider alignment with shareholders. The transaction size is modest relative to total holdings, so while it is a supportive signal, it is unlikely to materially affect control or valuation.
TL;DR: Insider buying is a positive behavioral signal but small relative to reported ownership; limited direct market impact.
The reported weighted-average purchase price range ($2.49鈥�$2.50) and the 6,000-share size are fully disclosed and routine. The incremental purchase increases direct beneficial ownership to 651,460 shares but represents a small percentage change versus that base. No derivative transactions or sales are reported. From a market-impact perspective, this disclosure is informational but not material in isolation.
David P. Hochman, Amministratore Delegato e Presidente di Orchestra BioMed Holdings, Inc. (OBIO), ha riferito di aver acquistato complessivamente 6.000 azioni ordinarie della societ脿 il 21/08/2025 a un prezzo medio ponderato di $2,49 per azione (i singoli ordini andavano da $2,49 a $2,50). Dopo l'acquisto dichiarato, il sig. Hochman detiene direttamente in propriet脿 beneficiaria 651.460 azioni e ulteriori azioni indirettamente tramite pi霉 trust familiari (posizioni indirette totali indicate: 449.331; 2.000; 2.000; 2.000; 3.140). Il Modulo 4 猫 stato firmato da un procuratore il 25/08/2025. La comunicazione evidenzia un acquisto da parte dell'amministratore delegato/presidente ma non fornisce motivazioni per le operazioni.
David P. Hochman, Director Ejecutivo y Presidente de Orchestra BioMed Holdings, Inc. (OBIO), inform贸 la compra de un total de 6.000 acciones ordinarias de la compa帽铆a el 21/08/2025 a un precio promedio ponderado de $2,49 por acci贸n (los precios individuales oscilaron entre $2,49 y $2,50). Tras la compra reportada, el Sr. Hochman posee beneficiariamente 651.460 acciones en forma directa y acciones adicionales de forma indirecta a trav茅s de varios fideicomisos familiares (posiciones indirectas totales indicadas: 449.331; 2.000; 2.000; 2.000; 3.140). El Formulario 4 fue firmado por un apoderado el 25/08/2025. La presentaci贸n revela la compra por parte del CEO/presidente pero no ofrece razones para las transacciones.
David P. Hochman, Orchestra BioMed Holdings, Inc. (OBIO)鞚� 斓滉碃瓴届榿鞛� 瓴� 鞚挫偓須� 鞚橃灔, 鞚� 2025-08-21鞐� 須岇偓 氤错喌欤� 齑� 6,000欤茧ゼ 欤茧嫻 臧�欷戫弶攴� $2.49鞐� 毵れ垬頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟(臧滊硠 瓯半灅臧�電� $2.49~$2.50). 氤搓碃霅� 毵れ垬 頉� Hochman 鞌姅 歆侅爲鞝侅溂搿� 鞙犾澋靻岇湢甓岇溂搿� 651,460欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅� 鞐煬 臧�臁� 鞁犿儊鞚� 韱淀暣 於旉皜搿� 臧勳爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟(氤搓碃霅� 臧勳爲 氤挫湢 頃╆硠: 449,331; 2,000; 2,000; 2,000; 3,140). Form 4電� 2025-08-25鞐� 雽�毽澑鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�. 鞝滌稖靹滌棎電� CEO/鞚橃灔鞚� 欤检嫕 毵れ垬 靷嫟鞚� 瓿店皽霅橃柎 鞛堨溂雮� 瓯半灅 靷湢電� 旮办灛霅橃柎 鞛堨 鞎婌姷雼堧嫟.
David P. Hochman, Directeur G茅n茅ral et Pr茅sident d'Orchestra BioMed Holdings, Inc. (OBIO), a d茅clar茅 avoir achet茅 au total 6 000 actions ordinaires de la soci茅t茅 le 21/08/2025 脿 un prix moyen pond茅r茅 de 2,49 $ par action (les prix des transactions individuelles variaient de 2,49 $ 脿 2,50 $). Apr猫s cet achat d茅clar茅, M. Hochman d茅tient directement 脿 titre b茅n茅ficiaire 651 460 actions et des actions suppl茅mentaires indirectement via plusieurs trusts familiaux (positions indirectes totales indiqu茅es : 449 331; 2 000; 2 000; 2 000; 3 140). Le formulaire 4 a 茅t茅 sign茅 par un mandat茅 le 25/08/2025. Le d茅p么t r茅v猫le un achat d'initi茅 par le PDG/pr茅sident mais ne fournit pas les raisons des op茅rations.
David P. Hochman, Chief Executive Officer und Vorsitzender von Orchestra BioMed Holdings, Inc. (OBIO), meldete den Kauf von insgesamt 6.000 Stammaktien des Unternehmens am 21.08.2025 zu einem gewichteten Durchschnittspreis von $2,49 je Aktie (Einzelhandelspreise lagen zwischen $2,49 und $2,50). Nach dem gemeldeten Erwerb besitzt Herr Hochman unmittelbar vorteilsberechtigt 651.460 Aktien sowie weitere Aktien indirekt 眉ber mehrere Familienstiftungen (angegebene indirekte Positionen gesamt: 449.331; 2.000; 2.000; 2.000; 3.140). Das Formular 4 wurde am 25.08.2025 von einem Bevollm盲chtigten unterzeichnet. Die Meldung zeigt einen Insiderkauf durch den CEO/Vorsitzenden, nennt jedoch keine Gr眉nde f眉r die Transaktionen.
FAQ
What did OBIO insider David P. Hochman report on Form 4?
How many OBIO shares does the reporting person own after the transaction?
Was the Form 4 signed and when?
Did the filing disclose any derivative transactions or sales?
What price range were the shares purchased at?
